MS: from disease management to patient management



Similar documents
29 January Rome, Italy

5 February Bari, Italy

13 September London, UK

Villejuif, Paris, France

I wish you an inspiring and successful learning experience here in Saint Petersburg. Yours Sincerely, Rachel Clark CEO, EXCEMED

Xavier Montalban Barcelona, Spain

Calendar of events NEUROLOGY

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April :10 14:20 Room C

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

PULMONARY HYPERTENSION. This meeting is fully sponsored by GlaxoSmithKline and jointly organised with the Meeting Faculty and GlaxoSmithKline

DoubleTree by Hilton Hotel Zagreb, Ulica Grada Vukovara 269a, Zagreb, Croatia

Paris 12 th December 2014

Magnetic Resonance Techniques in Neurodegenerative Diseases First Course Alzheimer s disease and frontotemporal lobar degeneration spectrum

STATE OF THE ART INVITATION SATURDAY, JANUARY 30 TH, 2016 COMORBIDITIES AND ENVIRONMENTAL FACTORS INFLUENCING MULTIPLE SCLEROSIS

Promises and challenges of developing new drugs in oncology

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

ACCORD PROJECT FINAL RESULTS OF THE. 2 nd June, Rafael Matesanz, on behalf of the ACCORD consortium. Director

The Copernican Revolution in Ischemic Heart Diseases: the day after

LIQUID BIOPSY: TRACKING CANCER

Scientific Programme

Magnetic Resonance Techniques in Multiple Sclerosis

GLOBAL SURVEY FACT SHEET

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis

Promises and challenges of developing new drugs in oncology

Biogen Global Medical Grants Office Multiple Sclerosis: Areas of Interest

ON CLINICAL PHARMACOLOGY OF ANTIRETROVIRALS 10 RESIDENTIAL COURSE January Starhotels Majestic. corso Vittorio Emanuele II 54 - TURIN

AOSpine Masters Symposium Adult deformity of the cervical, thoracic and lumbar spine

Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

SPONSOR AND EXHIBITOR INFORMATION

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Media Release. Basel, 8 October 2015

IPMSC First Scientific Conference Daily Program

EMD Serono Presents New Data on Rebif (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

SUMMER SCHOOL organised by the Hepatology Committee of ESPGHAN

CARDIOLOGIA E ARTE MILAN. December 1 st Grand Hotel Barone di Sassj. Sesto San Giovanni PRELIMINARY PROGRAM

Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS

Haploidentical Stem Cell Transplantation

Genomics in Hematology

on End Stage Focus on Idiopathic

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

MAY AUDITORIUM DEL SERAPHICUM. Via del Serafico, 1 - ROME - ITALY PRELIMINARY PROGRAM. Chairman: Giovanni Di Giacomo, MD

pulmonary hypertension bologna 2012 Royal Hotel Carlton - Bologna - Italy Under the aegis of alma mater studiorum università di bologna

International Conference on Clinical PET CT and Molecular Imaging: PET CT in the Era of Multimodality Imaging and Image Guided Therapy (IPET-2015)

Global Multiple Myeloma Epidemiology and Patient Flow Analysis

THE PRESENT AND THE FUTURE OF FERTILITY PRESERVATION

Travel Medicine Travel Medicine Vaccines & Therapeutics. Brochure. International Conference on. Travel Medicine 2016

Global Haemophilia Epidemiology and Patient Flow Analysis

Regional Young Investigator SIC meeting. 5-6 March 2015

Multiple Sclerosis: Current Treatments and Future Promise

Cachexia and Nutrition in Advanced Cancer Patients: a Multidisciplinary Approach Chairs: M.S. Aapro, CH J. Herrstedt, DK F.

First Announcement. 2 6 November 2014 Scottish Exhibition and Conference Centre Glasgow, UK. Joint Academic Sponsors

AORTA MASTERCLASS 2015 Preliminary Programme

INTERNATIONAL RETREAT OF PhD STUDENTS IN IMMUNOLOGY June 2015

Drug Safety of Stem Cells and other Novel Therapeutics

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

A LIFE THAT IS BORN MAKES LIFE GROW. CORD BLOOD: CURRENT EXPERIENCES AND FUTURE PROGRAMMES

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

Life with MS: Mastering Early Treatment

Department of Neurology and Neurosurgery Clinical and Clinical Research Fellowship Application Form

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Training for European Sustainable Tourism (T4EST)

9th World Congress on Prevention of Diabetes and its Complications. 2-4, December Georgia World Congress Centre, Atlanta, USA

FIRST INTERNATIONAL PORTO PIRGOS CONFERENCE ON ADVANCES IN NEUROSCIENCE. Porto Pirgos Hotel ( Parghelia (VV), Calabria, Italy

A Continuing Medical Education Podiatric Conference

FOCUS ON BIOLOGICAL THERAPIES IN HEMATOLOGIC MALIGNANCIES

Nutrition support in neurodegenerative diseases

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium

Welcome. AO Global Spine Congress Instructional Course Lectures.

Key Advances in Stroke Rehabilitation

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

Monday 27 th October ,00-14,00 Registration 12,30-14,00 Welcome Buffet

PROGRAM GENETIC AND EPIGENETIC ANALYSES OF HUMAN EMBRYOS: PAST, PRESENT AND FUTURE

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

A Handbook for Planning Committees Developing Educational Programs

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

The Importance of Educational Access for MS Nurses: Integrating Knowledge & Skills MS Nurse PROfessional

Section 1. Section Venue Registration Acknowledgement of Funding V: of 6

BREAST CANCER IN YOUNG WOMEN. OCTOBER 9 th 2015 Aula Magna UNIVERSITÀ DELLA SVIZZERA ITALIANA Lugano

Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Merck Serono UK Disclosure for 2014

Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Transcription:

2012 CME Annual meeting in multiple sclerosis MS: from disease management to patient management Valencia, Spain 18-19 May 2012

Dear Colleague On behalf of the Serono Symposia International Foundation we are delighted to welcome you to the 2012 annual continuing medical education (CME) accredited meeting: MS: from disease management to patient management. At this meeting, leading international experts will come together to discuss current and future approaches to the treatment of multiple sclerosis (MS). You will also have the opportunity to earn CME credits. This interactive meeting is divided into four sessions. Session 1 will cover the pharmacological targets of current and possible future therapies, and the requirement for close safety monitoring of newer therapies. In session 2 we will detail how the neurologist can best use the tools available for optimal diagnosis of MS and prediction of disease course. Session 3 will focus on current and future techniques to predict and monitor response to treatment, and in session 4 we will discuss the clinical management of MS, the relationship with the patient and how this can affect treatment adherence. Case studies will be presented, offering you the opportunity to discuss various aspects of clinical practice with the panel of experts. The aims of the 2012 annual conference are to provide an update on the latest understanding of MS pathophysiology and the mechanisms of action of current drugs, to discuss how best to diagnose patients and then predict and monitor treatment response, and to provide guidance on how best to ensure patients get optimal benefit from treatment. We anticipate that this programme will provide valuable updates for the clinician, and will stimulate engaging and enlightened debate on many of the complex issues surrounding the management of patients with MS. We hope that you will be able to join us and we look forward to your active participation. Yours sincerely, David Bates Newcastle upon Tyne, UK Xavier Montalban Barcelona, Spain All Serono Symposia International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. All Serono Symposia International Foundation programs are made possible thanks to educational grants received from: Centre d Esclerosi Multiple de Catalunya, ComtecMed, Congrex Sweden, Congrex Switzerland, Cryo-Save, Datanalysis, Esaote, European Society of Endocrinology, Fondazione Humanitas, Fundación IVI, ISFP International Society for Fertility Preservation, ISMH International Society of Men s Health, K.I.T.E., Merck Serono, Sanofi-Aventis, University of Catania, Vall d Hebron University Hospital.

AIM OF THE CONFERENCE LEARNING OBJECTIVES TARGET AUDIENCE ACCREDITATION Research into the pathophysiology of multiple sclerosis (MS) and the mechanism of action of new drugs has, in recent years, produced a virtuous circle offering ever-new insights, enhancing our understanding of the disease and allowing optimization of treatment. The 2012 Serono Symposia International Foundation (SSIF) annual meeting will provide a review of these insights and offer the opportunity to discuss how to translate this increasing knowledge of management improvements for individual patients. By attending the conference, participants will: be updated on MS pathophysiology and modes of action of individual drugs discuss the use of standardized diagnostic criteria in daily practice improve their skills in sharing information with patients to increase adherence understand present and future biomarkers of response to treatment. Clinicians involved in MS management. An application has been made to the EACCME for CME accreditation of the MS: from disease management to patient management conference, to be held on 18 19 May 2012 in Valencia, Spain. The official language of the conference will be English. REGISTRATION The full registration fee is 400,00 euro. For any registration requirements please contact Debora Urbinelli c/o Meridiano Congress International Tel. +39 (0)6 88 595 232 - Fax +39 (0)6 88 595 234 E-mail: d.urbinelli@meridiano.it 1

VENUE CHAIRS The conference will take place at: Meliá Valencia Palacio de Congresos Avenida Cortes Valencianas 52 Valencia, Spain David Bates Department of Neurology Royal Victoria Infirmary Newcastle upon Tyne, UK Xavier Montalban Multiple Sclerosis Centre of Catalonia Unit of Clinical Neuroimmunology Vall d Hebron University Hospital Barcelona, Spain SCIENTIFIC SECRETARIAT ORGANIZING SECRETARIAT Serono Symposia International Foundation Salita San Nicola da Tolentino, 1/B 00187 - Rome, Italy Senior Project Manager, Neurology Team Leader: Serena Dell Ariccia Associate Project Manager: Alessia Addessi Phone: +39 06 420 413 251/591 Fax: +39 06 420 413 677 info@seronosymposia.org Meridiano Congress International Via Mentana, 2/B 00185 - Rome, Italy Congress Coordinator: Debora Urbinelli Phone: +39 06 88 595 232 Mail: d.urbinelli@meridiano.it 2

Day 1 Friday, 18 May, 2012 08.15 SSIF Opening G. Comi (Italy) 08.30 Local welcome 08.45 Welcome and introduction D. Bates (UK) and X. Montalban (Spain) SCIENTIFIC PROGRAMME SESSION I Pharmacological targets and evolving pathophysiological concepts D. Bates (UK) 09.00 L1 Improving understanding of mechanism of action of immunomodulatory drugs B. Kieseier (Germany) 09.30 L2 Neuroprotection and neuroregeneration: the promising targets R. Gold (Germany) 10.00 L3 Resetting the immune system: stem cell transplantation A. Uccelli (Italy) 10.30 L4 Drug profile and efficacy G. Comi (Italy) 11.00 L5 Safety assessment in practice P. Vermersch (France) 11.30 Coffee break 3

SESSION II MS Diagnosis and prognosis X. Montalban (Spain) 12.00 L6 McDonald criteria 2010: making the diagnosis easier A.J. Thompson (UK) 12.30 L7 The diagnosis of MS before MS M. Tintorè (Spain) 13.00 L8 What MRI is telling us about individual disease evolution? D. Arnold (Canada) 13.30 Lunch 14.30 C1 Case study: Differential diagnosis: NMO vs MS Presenter: speaker to be confirmed Discussants: L. Moiola (Italy) and B. Kieseier (Germany) SESSION III Treatment monitoring 15.10 L9 Biomarkers G. Giovannoni (UK) 15.40 L10 MRI as a potential marker of response A. Rovira (Spain) 16.10 L11 Present and future roles of PGX J. Oksenberg (USA) 16.40 Coffee break 17.00 L12 Assessment of treatment response M. S. Freedman (Canada) 17.30 C2 Case study: Treatment and treatment algorithms Presenter: G. Comi (Italy) Discussant: X. Montalban (Spain) 18.10 End of the day 4

Day 2 Saturday, 19 May, 2012 SESSION IV From disease management to patient management G. Comi (Italy) 09.00 L13 The patient s willingness to take risk B. Kieseier (Germany) 09.30 L14 How to implement the partnership in clinical practice D. Langdon (UK) 10.00 L15 Treatment adherence: how to measure it and how to improve it J. Sastre-Garriga (Spain) 10.30 C3 Case study: Treatment failure due to lack of adherence Presenter: speaker to be confirmed Discussants: P. Rieckmann (Germany) and J. Sastre-Garriga (Spain) 11.10 C4 Case study: How to improve outcomes tailoring treatment Presenter: D. Bates (UK) Discussants: G. Giovannoni (UK) and P. Vermersch (France) 11.50 Concluding remarks 12.10 End of the conference and closing lunch 5

Improving the patient s life through medical education www.seronosymposia.org Serono Symposia International Foundation Representative Office Salita di San Nicola da Tolentino 1/B 00187 Rome, Italy. T +39.(0)6.420.413.1, F +39.(0)6.420.413.677 Headquarters 14, Rue du Rhone, 1204 Geneva, Switzerland Copyright Serono Symposia International Foundation, 2012. All rights reserved.